EmployblEmploybl logo
employbl
Be Biopharma logo

Be Biopharma Funding & Investors

Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.

be.bio

Total Amount Raised: $182,000,000

Be Biopharma Funding Rounds

  • Series B

    $130,000,000

    Series B Investors

    Arch Venture Partners
    Takeda Ventures
    Longwood Fund
    Ra Capital Management
    Alta Partners
    Atlas Venture
    Bristol-Myers Squibb

  • Series A

    $52,000,000

    Series A Investors

    Atlas Venture
    Ra Capital Management
    Takeda Ventures
    Longwood Fund
    Alta Partners
Funding info provided by Diffbot.